Somnath Mukherjee

Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial

T. Crosby, Stephen Falk, Simon Gollins et al. · The Lancet Oncology · 2013 · 381 citations · Full text

Medicine, Oncology, Surgery +17

Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline

Edward P. Balaban, Pamela B. Mangu, Alok A. Khorana et al. · Journal of Clinical Oncology · 2016 · 378 citations

Medicine, Radiation Oncology, Surgery +14

Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial

Somnath Mukherjee, John Bridgewater, Stephen Falk et al. · The Lancet Oncology · 2013 · 354 citations · Full text

Medicine, Oncology, Pharmacology +15

Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial

Paula Ghaneh, Daniel H. Palmer, Silvia Cicconi et al. · ˜The œLancet. Gastroenterology & hepatology · 2022 · 325 citations · Full text

Medicine, Oncology, Surgery +16

ESPAC-5F: Four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer.

Paula Ghaneh, Daniel H. Palmer, Silvia Cicconi et al. · Journal of Clinical Oncology · 2020 · 164 citations

Medicine, Oncology, Surgery +13